Recherches "plusieurs pathologies"
EXPRESS
Low level of genomic alteration to predict exceptional and unexpected response to targeted thÚrapies in patients with solid tumors.;EXPRESS : EXcePtional RESponSe
Paris
CHRISTOPHE LE TOURNEAU
Recherches "plusieurs pathologies"
MOST Plus
My Own Specific Treatment : A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with progressive locally-advanced or metastatic solid tumors
Paris
CHRISTOPHE LE TOURNEAU
Recherches "plusieurs pathologies"
SCANDARE (IC 2016-03)
Prospective biobanking study in ovarian, breast and head and neck cancer patients aiming at better understand the link between the molecular alterations of the tumor itself, its microenvironment and immune response.
Paris, Saint-Cloud
CHRISTOPHE LE TOURNEAU, CORALINE DUBOT
Recherches "plusieurs pathologies"
STARTRK-2 - GO40782
A Phase 2, Multicenter, Open-Label Study of Entrectinib for the Treatment of Locally Advanced or Metastatic NSCLC in Adult Patients with Tumors That Harbor NTRK1, NTRK2, NTRK3 or ROS1 Molecular Alterations
Paris
CHRISTOPHE LE TOURNEAU
Sein métastatique RH+
AIPAC
AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel
Saint-Cloud
ETIENNE BRAIN
Sein métastatique RH+
BYLieve (CBYL719X402)
A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment
Saint-Cloud
FLORENCE LEREBOURS
Sein métastatique RH+
COMPLEEMENT-1
An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease.
Paris, Saint-Cloud
PAUL-HENRI COTTU, FLORENCE LEREBOURS
Gynécologie - Col utérus
NiCOL (IC 2016-08)
A phase-I study of nivolumab in association with radiotherapy and cisplatin in locally advanced cervical cancers followed by adjuvant nivolumab for up to 6 months
Paris, Saint-Cloud
MANUEL RODRIGUES, CORALINE DUBOT
Sein métastatique RH+
PADA-1
Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HTdriven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients.
Paris, Saint-Cloud
FRANCOIS-CLEMENT BIDARD, CORALINE DUBOT